このアプリケーションの一部のコンテンツは現時点では利用できません。
このような状況が続く場合は、にお問い合わせくださいフィードバック & お問い合わせ
1. (WO2019064073) USE OF CA125 TO PREDICT ANTI-MESOTHELIN TREATMENT OF MESOTHELIOMAS



免責事項 PATENTSCOPE 上で提供される画像ファイル (PDF) が正式版です。ここに表示される HTML データは、利用者支援のために提供されるものです。データ作成の際には印刷文書や画像に含まれる情報が精密かつ正確に表されるよう細心の注意が払われていますが、データの伝送や変換に係る処理上の理由、また機械翻訳が行われる場合は (任意) 機械翻訳に固有の限界により、表示データに誤りや欠落が含まれる可能性があります。また、「」の記号が末尾に付されるハイパーリンクのリンク先は、WIPO により管理されない外部のリソースです。WIPO は、上記の点に関して一切の責任を負いません。

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/IB2018/001206 104018.001032
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
27 September 2018 27 September 2017
Applicant
EISAI R&D MANAGEMENT CO., LTD.
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
a. forming part of the international application as filed:
in the form of an Annex C/ST.25 text file.
on paper or in the form of an image file.
b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
c. furnished subsequent to the international filing date for the purposes of international search only:
in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.
In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.
Additional comments:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
USE OF CA125 TO PREDICT ANTI-MESOTHELIN TREATMENT OF MESOTHELIOMAS

5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No.     1a    
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     G01N 33/574 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     G01N
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, BIOSIS, EMBASE, INSPEC, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
R. HASSAN ET AL, "Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma", CLINICAL CANCER RESEARCH,Vol. 20, No. 23, 01 December 2014 (2014-12-01), page 5927-5936,
XP055340544
1-27
the whole document
In particular: Title; Abstract; Materials and methods; Figures 1 and 2; Page 5931, Biomarker assesment; Page 5934, columns 1 and 2, bridging paragraph.
(2)
X
RAFFIT HASSAN ET AL, "Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen", CANCER.,Vol. 120, No. 21, 01 November 2014 (2014-11-01), page 3311-3319,
XP055340553
1-27
the whole document
In particular: Title; Background; Materials and methods; Page 3316, Biomarker correlation and tumor response; Figure 4.
(3)
A
CHENG XU ET AL, "Clinical significance of serum CA125 in diffuse malignant mesothelioma", SPRINGERPLUS, SPRINGEROPEN, DE,Vol. 5, No. 1, 01 January 2016 (2016-01-01), page 368-8,
XP009510736
1-27
the whole document
In particular: Title; Abstract; Methods; Tables 2-5; Figure 3 and 4.
(4)
X,P
NICOLAIDES N C ET AL, "CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients", CANCER BIOLOGY & THERAPY, LANDES BIOSCIENCE, US,Vol. 19, No. 7, 03 July 2018 (2018-07-03), page 622-630,
XP009510735
1-27
the whole document
In particular: Title; Abstract; Table 1; Figures 1-4; Materials and methods.
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
25 January 2019
Date of mailing of the international search report:
01 February 2019
Authorized officer:
C.F. Angioni
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E